Public Sector Pension Investment Board Decreases Holdings in DexCom, Inc. $DXCM

Public Sector Pension Investment Board reduced its position in DexCom, Inc. (NASDAQ:DXCM) by 66.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,334 shares of the medical device company’s stock after selling 67,869 shares during the period. Public Sector Pension Investment Board’s holdings in DexCom were worth $2,310,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Jennison Associates LLC raised its position in DexCom by 9.4% during the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after acquiring an additional 994,300 shares during the last quarter. Marshall Wace LLP grew its position in shares of DexCom by 260.7% in the second quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock valued at $333,630,000 after purchasing an additional 2,762,504 shares during the last quarter. E. Ohman J or Asset Management AB increased its stake in shares of DexCom by 400.2% during the 3rd quarter. E. Ohman J or Asset Management AB now owns 77,492 shares of the medical device company’s stock worth $5,214,000 after purchasing an additional 62,000 shares in the last quarter. Zevenbergen Capital Investments LLC raised its position in shares of DexCom by 10.0% during the 3rd quarter. Zevenbergen Capital Investments LLC now owns 685,433 shares of the medical device company’s stock worth $46,123,000 after purchasing an additional 62,098 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in DexCom by 11.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,045 shares of the medical device company’s stock valued at $14,269,000 after buying an additional 21,352 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Up 1.1%

Shares of DXCM opened at $73.08 on Monday. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $91.87. The company’s fifty day moving average is $69.49 and its two-hundred day moving average is $69.26. The firm has a market cap of $28.13 billion, a PE ratio of 34.80, a price-to-earnings-growth ratio of 1.42 and a beta of 1.49. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the prior year, the firm posted $0.45 EPS. The business’s revenue for the quarter was up 13.1% on a year-over-year basis. Analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on DXCM shares. Robert W. Baird set a $87.00 price target on DexCom in a research report on Friday, February 13th. Wells Fargo & Company dropped their price objective on DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research report on Friday, February 13th. UBS Group cut their target price on shares of DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, November 3rd. Royal Bank Of Canada decreased their price target on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. Finally, Weiss Ratings downgraded shares of DexCom from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $85.18.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.